Hengrui Pharma's strategic ambition in oncology has focused on translating scientific innovation into meaningful treatment options for patients.
Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
Nataliya Andreychuk explains what teams must do before letting AI act on their behalf, and how that groundwork becomes a competitive advantage.
In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.
What constitutes a reliable supply chain is changing rapidly.
Editor's Picks
